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Abstract
There is increased interest in the potential protective role of dietary Ca in the development of metabolic disorders related to the metabolic
syndrome. Ca-induced intestinal precipitation of fatty acids and bile acids as well as systemic metabolic effects of Ca on adipose tissue
is proposed to play a causal role. In this experiment, we have studied all these aspects to validate the suggested protective effect of Ca
supplementation, independent of other dietary changes, on the development of diet-induced obesity and insulin resistance. In our diet
intervention study, C57BL/6J mice were fed high-fat diets differing in Ca concentrations (50 v. 150 mmol/kg). Faecal excretion analyses
showed an elevated precipitation of intestinal fatty acids (2·3-fold; P,0·01) and bile acids (2-fold; P,0·01) on the high-Ca diet. However,
this only led to a slight reduction in fat absorption (from 98 to 95 %; P,0·01), mainly in the distal small intestine as indicated by gene
expression changes. We found no effect on body-weight gain. Lipolysis and lipogenesis-related parameters in adipose tissue also
showed no significant changes on the high-Ca diet, indicating no systemic effects of dietary Ca on adiposity. Furthermore, early gene
expression changes of intestinal signalling molecules predicted no protective effect of dietary Ca on the development of insulin resistance,
which was confirmed by equal values for insulin sensitivity on both diets. Taken together, our data do not support the proposed protective
effect of dietary Ca on the development of obesity and/or insulin resistance, despite a significant increase in faecal excretion of fatty acids
and bile acids.
Key words: Dietary calcium: Obesity: Insulin resistance: Differential gene expression
The metabolic syndrome is a cluster of metabolic disorders
of which obesity and insulin resistance are considered the
major underlying risk factors. Because of the increasing
incidence of the metabolic syndrome worldwide, there is
increased interest in the potential protective role of dietary
Ca in the development of these metabolic disorders(1,2).
Human as well as rodent studies have previously shown
that dietary Ca increases faecal fat excretion by the
formation of insoluble Ca-fatty acid soaps in the intestinal
lumen(3–6). This Ca-driven lowering of fat absorption is
suggested to be a potential dietary intervention to prevent
or at least reduce weight gain and adiposity in the current
society. However, studies conducted so far do not provide
a conclusive answer regarding the effect of Ca supplemen-
tation, independent of other changes in the diet (e.g. dairy
intake), on faecal fat excretion and its association with a
reduction in weight gain or adiposity(4,7,8).
Next to precipitation of fatty acids, dietary Ca is also
able to bind bile acids in the intestinal lumen, thereby
increasing faecal bile acid excretion(3,4,9). Interestingly,
Kobayashi et al.(10) previously reported that bile acid-
binding resins ameliorated diet-induced obesity and insulin
resistance, presumably by reducing fat accumulation in the
liver and subcutaneous fat. Studies with diabetic patients
have also showed that a reduced hepatic lipid accumu-
lation was associated with improved insulin sensitivity
and normalised gluconeogenesis(11,12). On the contrary,
an increased faecal bile acid excretion may also imply a
reduced enterohepatic circulation of bile acids, which
might consequently diminish energy expenditure accord-
ing to Watanabe et al.(13). This might then induce an
adverse effect of bile acids on body-weight gain.
A more systemic effect of Ca on adiposity is suggested
by Zemel(14). According to their hypothesis, high dietary
Ca intake is associated with reduced plasma 1,25-vitamin
D and parathyroid hormone (PTH) levels. This would
then lead to a decreased Ca ion influx into adipocytes,
eventually resulting in the stimulation of lipolysis and the
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inhibition of lipogenesis. Ca supplementation trials in
human subjects and aP2-agouti transgenic mice conducted
by Zemel(14) confirmed an inverse association between Ca
and adiposity. This protective effect of Ca was, however,
not found in many other intervention trials(15–18). Thus,
conclusive evidence for a systemic effect of dietary Ca is
again lacking.
In the present study, we investigated the effect of Ca
supplementation on precipitation of fatty acids and bile
acids in the intestinal lumen, as well as the systemic effects
of dietary Ca in relation to the development of the meta-
bolic syndrome. Therefore, we fed C57BL/6J mice a high-
fat diet with a low Ca concentration that mimics a habitual
Western-type human diet, with a Ca intake of about
1000 mg/d(19), or a high-fat diet with a three times higher
Ca concentration. In contrast to several related diet inter-
vention studies that have suggested a protective effect of
Ca on obesity and insulin resistance, in the present study,
Ca is the only nutritional compound that differs in concen-
tration between the high-fat diets. Our effects are therefore
due solely to dietary Ca. Moreover, the chosen dietary Ca
concentrations in the high-fat diets support extrapolation
to the human situation.
Methods
Animals and diets
Male C57BL/6J mice were purchased from Harlan (Horst,
The Netherlands) and were housed two per cage in the
light- and temperature-controlled animal facility of Wagen-
ingen University. They had free access to water, and before
the diet intervention, they received standard laboratory
chow (RMH-B; Arie Blok BV, Woerden, The Netherlands).
For all experiments, the institutional and national guide-
lines for the care and use of animals were followed, and
all experiments were approved by the Local Committee
for Care and Use of Laboratory Animals at Wageningen
University.
After a run-in period of 3 weeks on a low-fat diet,
9- to 12-week-old mice were fed a palm oil-rich, high-fat
purified diet with either a low (LCa diet, 50 mmol/kg) or
high concentration of Ca (HCa diet, 150 mmol/kg) for
8 weeks. Dicalcium phosphate and calcium carbonate
were the sources of dietary Ca. The diets were composed
by Research Diet Services (Wijk bij Duurstede, The Nether-
lands), and their complete composition is given in the
supplementary material (Additional file 1, available online
at http://www.journals.cambridge.org/bjn). Note that a
low-fat-diet group was also included in this diet interven-
tion study to ensure high-fat diet-induced development
of obesity and insulin resistance (data previously pub-
lished(20)). During the diet intervention, body weight was
recorded weekly. After 2 weeks of intervention, six mice
per diet group were killed in the fed state. The small intes-
tines were excised, and the adhering fat and pancreatic
tissue were carefully removed. The small intestines were
divided into three equal parts along the proximal-to-distal
axis (proximal, middle and distal part of the small intes-
tine). Small-intestinal mucosal cells were scraped, snap-
frozen in liquid N2 and stored at 2808C until RNA isolation.
At week 7, an oral glucose tolerance test was performed;
after a 6 h fast, six mice per diet group received 0·5 ml of
a 20 % glucose solution via oral administration, and
blood glucose was measured after 15, 30, 45, 60, 90 and
150 min using Accu-Chek blood glucose meters (Roche
Diagnostics, Almere, The Netherlands). At week 8, twelve
mice per diet group were killed after a 6 h fast to determine
parameters of (hyper)glycaemia in blood and to perform
lipid metabolism-related measurements in epididymal
white adipose tissue. White adipose tissue was weighed,
snap-frozen in liquid N2 and stored at 2808C until RNA iso-
lation. Approximately 1 ml blood was collected in micro-
tubes containing 1·6 mg EDTA (Sarstedt AG & Co,
Nu¨mbrecht, Germany). Plasma was obtained after centrifu-
gation at 11 000 g for 10 min and frozen at 2808C. Before
the killing at weeks 2 and 8, mice were anaesthetised
with isoflurane (1·5 % in 70 % nitrous oxide/30 % oxygen).
Faecal and plasma analyses
After 5 weeks of diet intervention, faeces were collected for
48 h. Faeces were lyophilised, weighed and homogenised.
Total NEFA and total bile acids in faeces were deter-
mined as described previously(3). Appropriate standards
and reference samples were assayed simultaneously. The
recovery of added standards always exceeded 95 %.
The absorption efficiency of dietary fat was calculated by
subtracting the faecal amounts of fat excreted per d from
the daily fat intake.
Plasma NEFA were assayed enzymatically (NEFA-C kit;
Wako Chemicals, Neuss, Germany), and plasma PTH was
measured using the Mouse Intact PTH ELISA kit (Immuno-
topics, Inc., San Clemente, CA, USA). Plasma insulin levels
were detected by the Insulin (Mouse) Ultrasensitive EIA
(Alpco Diagnostics, Salem, NH, USA) and glycated Hb
(HbA1C) using the A1cNowþ test (Metrika BV, Sunnyvale,
CA, USA).
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen,
Breda, The Netherlands) according to the manufacturer’s
instructions. The isolated RNA was further column-purified
using the SV total RNA isolation system (Promega, Leiden,
The Netherlands). RNA concentration was measured on a
NanoDrop ND-1000 UV–Vis spectrophotometer (Isogen,
Maarssen, The Netherlands) and analysed on a bioanalyser
(Agilent Technologies, Amsterdam, The Netherlands) with
6000 Nano Chips (Agilent Technologies) according to the
manufacturer’s instructions.
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B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
Complementary DNA synthesis and real-time
quantitative PCR
Single-stranded complementary DNA was synthesised
from 1mg of total RNA using the Reverse Transcription
System (Promega) following the supplier’s protocol.
Complementary DNA was PCR amplified with Platinum
Taq DNA polymerase (all reagents were from Invitrogen).
Primer sequences used for real-time quantitative PCR
were chosen based on the sequences available in the
GenBank database (www.ncbi.nlm.nih.gov), and these
are listed in the supplementary material (Additional file 2,
available online at http://www.journals.cambridge.org/
bjn). Quantitative PCR were performed using SYBR green
(Invitrogen Molecular Probes) and a MyIQ thermal cycler
(Bio-Rad Laboratories BV, Veenendaal, The Netherlands).
The following thermal cycling conditions were used:
8 min at 948C, followed by forty-five cycles at 948C for
15 s and 608C for 1 min. PCR were performed in duplicate,
and all samples were normalised to cyclophilin A
expression.
Microarray hybridisation and analysis
For each part of the small intestine, total RNA was
pooled per diet group (n 6). RNA was hybridised to
Mouse Genome 430 2.0 arrays (Affymetrix, Santa Clara,
CA, USA). Detailed methods for the labelling and
subsequent hybridisations to the arrays are described in
the eukaryotic section of the GeneChip Expression
Analysis Technical Manual Rev. 3 from Affymetrix, which
is available upon request. Arrays were scanned on an
Affymetrix GeneChip Scanner 3000 (Affymetrix). Data
analysis was performed in MAS 5.0, which is also
provided by Affymetrix. To estimate the magnitude and
direction of differential gene expression, MAS 5.0 software
provides signal log ratios. If the signal log ratio is equal
to or greater than zero, fold change is obtained with
2(signal log ratio), otherwise (21) £ 22(signal log ratio). Based
on perfect match and mismatch probes, MAS 5.0 software
also calculates the significance of differential gene
expression. Array data have been submitted to the Gene
Expression Omnibus accession numbers GSE8582 and
GSE18581.
Statistical analysis
Physiological data and quantitative PCR results are
reported as means with their standard errors. The differ-
ences between the mean values were tested for statistical
significance by the independent samples t test (PASW
Statistics 17.0 software; SPSS, Inc., Chicago, IL, USA).
In short, this means that based on Levene’s t test for
equality of variance, ‘equal variances assumed’ or ‘equal
variances not assumed’ t tests were used. P values
,0·05 are considered to be statistically significant.
Results
Dietary calcium precipitates fatty acids and bile acids in
the gut lumen
First, we determined the capacity of the HCa diet to pre-
cipitate dietary fat and bile acids in the small-intestinal
lumen (Table 1). We found a significant increase in faecal
fat and faecal bile acids on a HCa diet compared with a
LCa diet. To gain more insight into the effect of dietary
Ca on the absorption of fat, we used food intake measure-
ments and faecal excretion data to estimate absolute values
and percentages of absorbed dietary fat. Table 1 shows that
there is a significant difference in the percentages of fatty
acid absorption on a HCa and LCa diet; however, the absol-
ute values are very close together and are not significantly
different. Furthermore, the increase in faecal bile acid
excretion indicates a reduced reabsorption of bile acids
in the small intestine.
The effect of dietary calcium on high-fat diet-induced
obesity and adiposity
To determine the effect of dietary Ca on obesity, we
measured food intake and body weight. We found that
energy intake on the LCa (59·8 (SE 1·7) kJ/d) diet was
slightly lower, but was not significantly different from
that on the HCa diet (61·9 (SE 1·7) kJ/d). Fig. 1 shows
that mice on the LCa and HCa diets gained equal weight
during the 8 weeks of diet intervention. However, this
did not exclude the possibility that the ratio between fat
mass and lean mass differed between mice on the HCa
and the LCa diets. To study the proposed effect of dietary
Ca on adipose tissue, we first analysed epididymal fat pads
for weight and determined gene expression of the lipogen-
esis marker fatty acid synthase and the lipolysis marker
hormone-sensitive lipase. The weights of epididymal fat
pads were not significantly different between the LCa
and HCa diets (2·4 (SE 0·1) and 2·5 (SE 0·1) g, respectively).
Also, fatty acid synthase and hormone-sensitive lipase
showed no differential gene expression (Fig. 2). Addition-
ally, we measured plasma NEFA and plasma PTH levels to
determine Ca-induced changes in the rate of lipolysis. We
found no significant differences in plasma NEFA and PTH
Table 1. Faecal fat and bile acid excretion
(Mean values with their standard errors)
LCa HCa
Mean SE Mean SE P
Dietary fat intake (mg/d) 747·1 36·0 748·8 15·9 0·96
Faecal fat (mg/d) 17·9 1·6 41·2 3·7 ,0·01
Fat absorption (mg/d) 729·2 34·9 707·7 13·4 0·49
Fat absorption
(% of daily intake)
97·6 0·2 94·6 0·4 ,0·01
Faecal bile acids (mmol/d) 1·4 0·1 2·8 0·3 ,0·01
LCa, high-fat, low-Ca diet; HCa, high-fat, high-Ca diet.
Calcium does not protect against obesity 1007
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after 8 weeks of LCa and HCa diet intervention (Table 2).
Together, our data indicate that dietary Ca has no effect
on fat-induced obesity and adiposity.
Dietary calcium-induced changes in small-intestinal gene
expression
In a previous study, we found that dietary fat-induced gene
expression changes in the small intestine could already be
detected after 2 weeks of diet intervention(20). Therefore,
we now also performed microarray analysis of mucosal
scrapings after 2 weeks of LCa and HCa diet intervention
to determine whether the effects of dietary Ca on precipi-
tation, and therefore also (re)absorption of fatty acids and
bile acids, modulate gene expression (Table 3). For lipid
metabolism-related genes, we found hardly any changes
in the proximal and middle part of the small intestine,
where most of the fatty acids are usually absorbed. In the
distal part of the small intestine, however, dietary Ca
induced a decrease in the expression of genes, which are
key regulators in the catabolism of fatty acids (Cpt1a,
b-oxidation; Cyp4a10, v-oxidation; Hmgcs2, ketogenesis).
No or minimal gene expression changes could be deter-
mined in fatty acid transport and chylomicron synthesis.
As expected, the most pronounced changes in gene
expression related to bile acid metabolism were seen in
the distal part of the small intestine, as this is where reab-
sorption occurs. We found a small down-regulation of
Fgf15 and an up-regulation in apical (Slc10a2) and basolat-
eral (Ostb) bile acid transporters.
According to the hypothesis of Kobayashi et al.(10), bind-
ing of bile acids in the intestinal lumen might prevent the
development of insulin resistance. To get a first impression
whether the Ca-induced precipitation of bile acids that
we found in the present study could indeed prevent the
development of insulin resistance, we determined gene
expression of the intestinal signalling molecules Angptl4,
Igfbp3, Mif and Il18. An up-regulation of Angptl4, Igfbp3
and Mif and a down-regulation of Il18 were previously
found to be associated with the onset of dietary fat-induced
insulin resistance(20). In this study, we found a dietary
Ca-induced up-regulation of Angplt4, Mif and Il18 and no
differential gene expression of Igfbp3, after 2 weeks of
diet intervention.
The effect of dietary calcium on high-fat diet-induced
insulin resistance
To ascertain that the early Ca-induced gene expression
changes in intestinal signalling molecules precede the
development of insulin resistance, we performed an oral
glucose tolerance test after 7 weeks of diet intervention
(Fig. 3). We found no significant difference in blood glu-
cose clearance between the diets, although the area
under the curve was slightly higher on the HCa diet
(P¼0·1). Additionally, at the end of the diet intervention,
we measured the percentage of glycated Hb (HbA1C) in
the plasma and calculated the homeostasis model assess-
ment for insulin resistance index from fasting glucose
and fasting insulin levels (fasting glucose £ fasting insu-
lin/22·5) (Table 4). We also found no significant differences
for these parameters between the LCa and HCa diets, but
together with the oral glucose tolerance test data, the
present results suggest a slightly compromised insulin
sensitivity on the HCa diet. This is in accordance with the
early gene expression changes of Angptl4 and Mif.
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Fig. 2. Fatty acid synthase (Fasn) and hormone-sensitive lipase (Hsl)
expression in epididymal white adipose tissue. Gene expression in epididy-
mal white adipose tissue of the lipogenesis marker Fasn and lipolysis marker
Hsl after 8 weeks of high-fat, low-Ca diet (LCa, A) and high-fat, high-Ca diet
(HCa, ) intervention, analysed by quantitative PCR. Values are means,
with standard errors represented by vertical bars.
16
14
12
10
8
6
4
2
0
0 1 2 3 4 5 6 7 8
Weeks of diet intervention
W
ei
g
h
t 
ga
in
 (
g
)
Fig. 1. Body-weight gain. Body weight of C57BL/6J mice was recorded
weekly during a diet intervention of 8 weeks. Values are means, with stan-
dard errors represented by vertical lines. LCa, high-fat, low-Ca diet (–W–);
HCa, high-fat, high-Ca diet (–X–).
Table 2. Fasting plasma concentration of lipolysis-related markers
(Mean values with their standard errors)
LCa HCa
Mean SE Mean SE P
NEFA (mm) 211·7 4·4 208·4 2·5 0·48
Intact PTH (pg/ml) 83·1 7·3 86·8 16·9 0·85
LCa, high-fat, low-Ca diet; HCa, high-fat, high-Ca diet; PTH, parathyroid hormone.
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Discussion
In the present study, we clearly showed that dietary Ca
precipitates fatty acids and bile acids in the small intestinal
lumen and thereby increases the faecal excretion of both
components. For fatty acids, we calculated that this
increase in faecal excretion on the HCa diet leads to a
slight decrease in the percentage of dietary fat that is
absorbed. This change in fat absorption is most pro-
nounced in the distal part of the small intestine based on
our gene expression data. Nevertheless, the absolute
values of absorbed dietary fat on a HCa and LCa diet are
still very similar and are not significantly changed by diet-
ary Ca. This could explain why we do not see a lower
weight gain on the HCa diet, which contrasts with the
hypothesis proposed by Astrup and co-workers(4,8).
The dietary Ca-induced down-regulation of Fgf15, a
target gene of the nuclear bile acid receptor farnasoid X
receptor(21), suggests a decreased bile acid reabsorption
on a HCa diet. The decreased expression of Fgf15 is prob-
ably a compensatory mechanism for the faecal loss of bile
acids on a HCa diet, as reduced Fgf15 signalling triggers
the liver to increase the bile acid synthesis(22). This is in
accordance with other studies that reported an increase
in biliary bile acid secretion upon increased faecal
excretion of bile acids(10,23). Kobayashi et al.(10) reported
that an increase in bile acid synthesis, which is induced
by bile acid-binding resin, results in changes in lipid and
glucose metabolism which are related to reduced obesity
and insulin resistance. However, as we found no effect of
dietary Ca on fat-induced obesity and insulin resistance,
Table 3. Diet-induced differential gene expression in the small-intestinal mucosa
Gene name Symbol Proximal SI* Middle SI* Distal SI*
Lipid metabolism
Fatty acid transport
Solute carrier family 27, member 2 Slc27a2 NC NC NC
Fatty acid catabolism
Carnitine palmitoyltransferase 1a Cpt1a NC NC 21·36
Cytochrome P450, family 4 subfamily a, polypeptide 10 Cyp4a10 NC NC 21·48
3-Hydroxy-3-methylglutaryl-CoA synthase 2 Hmgcs2 1·29 1·35 21·36
Chylomicron synthesis
apo B Apob NC NC NC
apo C-II Apoc2 NC NC 1·26
apo C-III Apoc3 NC NC NC
Microsomal TAG transfer protein Mttp NC NC NC
Bile acid metabolism
Bile acid transport
Ileal bile acid-binding protein Ibabp, Fabp6 A 22·00 NC
Organic solute transporter b Ostb NC NC 1·33
Solute carrier family 10, member 2 (Asbt) Slc10a2 A A 1·84
Negative feedback hepatic bile acid synthesis
Fibroblast growth factor 15 Fgf15 A A 21·16
Secreted (signalling) molecules
Angiopoietin-like 4 Angptl4 1·55 1·59 1·34
Insulin-like growth factor-binding protein 3 Igfbp3 NC NC NC
IL-18 Il18 NC NC 1·67
Macrophage migration inhibitory factor Mif NC 1·15 1·45
SI, small intestine; NC, no change; A, absent.
* Differential gene expression is indicated by fold changes of HCa/LCa. Positive and negative numbers indicate a significant up- and down-
regulation, respectively.
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Fig. 3. Oral glucose tolerance test. An oral glucose tolerance test was
performed after 7 weeks of diet intervention. After oral administration of 100mg
glucose, blood glucose levels were monitored for 150 min. The changes in blood
glucose levels and the area under the curve (AUC) were calculated (see inset;
P¼0·1). Values are means, with standard errors represented by vertical lines.
LCa, high-fat, low-Ca diet (–W–); HCa, high-fat, high-Ca diet (–X–).
Table 4. Physiological parameters that are (in)directly associated with
insulin sensitivity
(Mean values with their standard errors)
LCa HCa
Mean SE Mean SE P
HbA1C (%) 4·6 0·1 4·7 0·1 0·23
Fasting glucose (mmol/l) 10·3 0·3 10·3 0·3 0·94
Fasting insulin (pmol/l) 249·3 42·4 218·3 30·9 0·56
HOMA-IR 17·0 3·6 14·7 2·3 0·57
LCa, high-fat, low-Ca diet; HCa, high-fat, high-Ca diet; HbA1C, glycated Hb;
HOMA-IR, homeostasis model assessment for insulin resistance.
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we conclude that the effects of bile acid-binding resins on
these metabolic disorders cannot be extrapolated to dietary
Ca. The unexpected up-regulation of bile acid transporters
Slc10a2 and Ostb that we found in the present study can
be explained by the relative increase of hydrophilic bile
acids in the intestinal lumen on the HCa diet, as Ca predomi-
nantly precipitates hydrophobic bile acids(24). Asamoto
et al.(25) previously found that hydrophilic bile acids are
associated with an induction of bile acid transporters. The
up-regulation of Slc10a2 and Ostb also implies that the Ca-
induced increase in faecal excretion of bile acids does not
necessarily lead to a reduced enterohepatic circulation(26)
and a consequent reduction in energy expenditure(13).
In contrast to the hypothesis of Zemel(14,27), the low
(50 mmol/kg, 0·2 %) v. high Ca concentrations (150 mmol/
kg, 0·6 %) in our high-fat diets did not induce differences
in body-weight gain and adiposity after an 8-week diet
intervention. A similar result for body weight was recently
described by Zhang & Tordoff (17) using dietary Ca concen-
trations that were highly comparable to the ones we used
in the present study as well as higher Ca concentrations
(1·8 %), all of which were not effective in the regulation
of body weight. One might argue that the Ca concentration
in the LCa diets (0·2 %) used in Zhang’s and the present
study was still adequate for optimal metabolic functioning
and that therefore no effects on adiposity could be found.
Our LCa diet mimics a human Ca intake of 1000 mg/d,
assuming a daily food intake of 500 g dry weight. The
results of the present study are in line with recent human
studies, in which obese adults were supplemented with
1500 mg Ca/d for 3 months or 2 years, showing no effect
of dietary Ca on body weight, lipid oxidation or lipoly-
sis(16,28). Note that in these studies, subjects with a habitual
Ca intake exceeding 850 mg/d or even 700 mg/d were
excluded. Zemel et al., who used Ca concentrations in
the diets ranging from 0·4 to 2·4 %, based their hypothesis
of dietary Ca-induced inhibition of lipogenesis and stimu-
lation of lipolysis mainly on aP2-agouti transgenic mice
studies. They found a dietary Ca-induced reduction in
body weight(29). However, this transgenic mouse model
of diet-induced obesity is probably not very representative
for effects in wild-type mice. Parra et al.(30) did report an
anti-obesity effect of dairy Ca in wild-type C57BL/6J
mice. However, similar to the studies in aP2-agouti trans-
genic mice, the compared diets did not differ only in Ca
content, but also contained variations in casein and sucrose
concentrations. These additional dietary changes might
very well also have an effect on the regulation of body
weight(31,32). Moreover, in contrast to the present study, a
substantial amount of Ca in their diets was derived from
dairy products. There is growing evidence that other com-
ponents in dairy products, such as medium-chain fatty
acids, and dairy proteins work synergistically with Ca to
alter lipid metabolism(1,18,33,34).
After 2 weeks of diet intervention, the gene expression
data of intestinal signalling molecules Angptl4, Igfbp3
and Mif already indicated no preventive effect of dietary
Ca on the development of insulin resistance. Only the
up-regulation of Il18 suggested a preventive effect of
dietary Ca-induced precipitation of bile acids on the deve-
lopment of insulin resistance. After 7 and 8 weeks of diet
intervention, we measured multiple physiological par-
ameters that are directly or indirectly associated with insu-
lin sensitivity. Next to an oral glucose tolerance test and
HbA1C, we measured fasting glucose and fasting insulin
to calculate the homeostasis model assessment for insulin
resistance index. The homeostasis model assessment for
insulin resistance index is a commonly used measure of
insulin sensitivity in rodent studies; however, note that
it should be interpreted with caution as it was never
validated for animal models. Surprisingly, both gene
expression data and physiological parameters suggest
even a slightly worsened insulin sensitivity on the HCa
diet. In accordance with the present results, Hoppe
et al.(35) previously reported that a short-term high milk
intake leads to increased insulin resistance. A possible
explanation for this impairment in insulin sensitivity on a
high dietary Ca intake might be a lowered absorption
of Mg due to the formation of an insoluble calcium–
magnesium–phosphate complex in the intestinal lumen(36).
Changes in Mg intake were previously linked to insulin
resistance(37,38). However, further research is necessary
to gain more insight into this phenomenon.
In conclusion, the present study showed no protective
effect of dietary Ca on the development of fat-induced
obesity and/or insulin resistance, despite the significant
increase in faecal excretion of fatty acids and bile acids
on a HCa diet. Therefore, the present results do not sup-
port hypotheses which suggest that Ca by itself has the
capacity to regulate body weight, adiposity and insulin
sensitivity.
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